MarketPulse

Behçet's Disease

4 articles
BenzingaBenzinga··Soligenix, Inc.

Soligenix Burns Through Cash as Rare Disease Pipeline Awaits Make-or-Break 2026 Trials

Soligenix reported zero 2025 revenue and $11.1M net loss. Company has $7.9M cash, seeking partnerships to fund operations through Q4 2026 pivotal trials.
SNGXPhase 3 clinical trialbiopharmaceutical
BenzingaBenzinga··Prnewswire

Soligenix Wins EU Orphan Status for Behçet's Disease Drug SGX945

Soligenix's dusquetide (SGX945) receives EU orphan drug designation for Behçet's Disease, backed by Phase 2a data showing 40% ulcer reduction with no adverse events.
SNGXrare diseaseclinical trial
BenzingaBenzinga··Prnewswire

Soligenix's SGX945 Earns UK Innovative Medicine Designation for Behçet's Disease

Soligenix's SGX945 earns UK Promising Innovative Medicine designation for Behçet's Disease, enabling early patient access with Phase 2 data showing 40% ulcer improvement.
SNGXrare diseaseBehçet's Disease
BenzingaBenzinga··Prnewswire

Soligenix Wins EMA Backing for SGX945 Orphan Drug Status in Behçet's Disease

Soligenix wins EMA orphan drug designation backing for SGX945 treating Behçet's Disease, following positive Phase 2a results and prior FDA support.
SNGXrare diseaseclinical trial